Navigation Links
US FDA Grants Pediatric Exclusivity for UCB's Keppra(R)
Date:6/6/2008

43.1% of levetiracetam-treated patients experiencing at least a 50% reduction in seizure frequency during the evaluation period (five days) compared with 19.6% of placebo-treated patients (p=0.013). Levetiracetam was generally well-tolerated in this pediatric population. The most commonly reported adverse events that occurred more frequently in the treatment group were somnolence (13.3% vs. 1.8% for placebo) and irritability (11.7% vs. 0 for placebo). The incidence of other adverse events was similar in both groups.

In October 2007, UCB announced that it had reached an agreement to settle pending patent infringement lawsuits in the US. Under the terms of the settlement agreement with Mylan, and subject to its receiving FDA approval, Mylan will be allowed to sell its generic levetiracetam tablets effective November 1, 2008, in advance of the expiry of UCB's market exclusivity on January 14, 2009.

About Epilepsy: Epilepsy is a chronic neurological disorder affecting 40 million people worldwide including 2.5 million people in the US. It is caused by abnormal, excessive electrical discharges of the nerve cells or neurons in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes and effective classification guides treatment and prognosis. Between 70-80% of individuals are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures or significant adverse side effects secondary to medication highlighting the ongoing need for the development of new antiepileptic drugs.

About Keppra(R) in the US: Keppra(R) (levetiracetam) tablets were first approved by the FDA in 1999 as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. Since 1999, Keppra(R) has received several supplemental indications
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
2. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
3. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
4. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
5. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
6. European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
7. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. United States Patent Office Grants CryoCors Request for Patent Interference
10. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013  Organogenesis ... medicine, presented new data generated in collaboration with a ... health economics consultancy) demonstrating the significant healthcare resource and ... leg ulcers (VLU) place upon the US healthcare system. ... reveal annual costs of up to $15 billion and ...
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) , ... pleased to announce a sponsorship agreement with Erebus Motorsport ... distributor of DrugCheck® onsite testing devices, manufactured by EDI. ... Austin 400 May 17-19 in Austin, Texas. , Royal ... each car of the Erebus Motorsport team displaying the ...
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Through science ... and funds for lab equipment, 25 organizations will continue ... importance of optics and photonics in daily life with ... , The organizations, located in 10 countries, are the ... be awarded by SPIE, the international society for ...
Breaking Biology Technology:Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3
... -- A new type of active metamaterial that incorporates ... ability to have power gain while retaining its negative ... research. "Our simulation and experimental results show that ... only provided gain, but also maintained the negative index ...
... 9, 2011 ARUP Laboratories, pathologist, Ronald L. Weiss, ... the College of American Pathologists at CAP ,11, the ... According to the CAP, the award honors members "who ... care through the specialty of pathology." (Logo: ...
... NewCardio, Inc., (OTC BB: NWCI) a cardiovascular diagnostic ... will utilize QTinno®, NewCardio,s automated cardiac safety solution, to ... drug under development for a central nervous system (CNS) ... important aspect of the trial. Clinilabs, located ...
Cached Biology Technology:New metamaterial allows transmission gain while retaining negative refraction property 2ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5
(Date:5/22/2013)... screening for prostate cancer could become as easy for ... to UC Irvine research published today in the ... more than a decade of work, UC Irvine chemists ... markers for prostate cancer in urine, meaning that the ... and at dramatically lower cost. The same technology could ...
(Date:5/21/2013)... have known for a long time that some creatures ... understood, particularly for plants. But it may be that ... National University and the U. S. National Evolutionary Synthesis ... 21 May in the journal Nature Communications , ... genomes. , Drawing from a database of global patterns ...
(Date:5/21/2013)... Wash. A new analysis shows that the nation,s ... of enough algae to produce up to 25 billion ... States, one-twelfth of the country,s yearly needs. , The ... resources that would be needed to grow significant amounts ... results were published in the May 7 issue of ...
Breaking Biology News(10 mins):UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Small but speedy: Short plants live in the evolutionary fast lane 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4
... NARRAGANSETT, R.I. August 30, 2010 The ... the University of Rhode Island Graduate School of ... Foundation (NSF) RAPID Response grant through the Foundation,s ... NSF grant, Improving Communication of Oil Spill Research, ...
... It is not an easy task to compare the ... by conventionally fuelled automobiles. The degree to which manufacture, ... the necessary electrical energy are detrimental to the environment ... a team of Empa scientists have made a detailed ...
... MADISON, WI, August 30th, 2010 Undergrads often take ... Iowa State University Department of Horticulture teamed up with ... section to teach students to research and understand literature ... Andrea L. Dinkelman, Jeanine E. Aune, and Gail R. ...
Cached Biology News:Metcalf Institute wins NSF grant to help journalism and communication of oil spill research 2'Greener' than expected 2'Greener' than expected 3Teaching communication and information literacy skills 2
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Biology Products: